MedPath

Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g

Not Applicable
Active, not recruiting
Conditions
Infant, Newborn, Diseases
Infant Development
Interventions
Dietary Supplement: Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748
Registration Number
NCT05945017
Lead Sponsor
Fundacion Clinic per a la Recerca Biomédica
Brief Summary

Unicentric, quasi-experimental, cohort study to evaluate the effect of combining two probiotics (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) in the neurodevelopment of preterm neonates below 32 weeks' gestation and a birthweight under 1,500 g. This probiotic combination has shown to be safe and beneficial in premature neonates in the prevention of NEC. The investigators hypothesised that this mixture would contribute to better neurodevelopmental outcomes of preterm neonates when assessed at 24 months corrected age. Additionally, neurodevelopment improved would be more relevant at 6 years of age, together with a better pattern of neuronal plasticity biomarkers.

Secondarily, this mixture of probiotics could reduce NEC, LOS, intraventricular haemorrhage and neonatal mortality in accordance with previous studies.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
233
Inclusion Criteria
  • Premature infants under 32 weeks gestational age and less than 1500g birthweight.
  • Born at BCNatal Hospital Clínic between years 2014-2019.
Exclusion Criteria
  • All neonates presenting with suspected congenital anomalies, inborn errors of metabolism, or genetic defects were excluded.
  • Infants with a suspected syndrome, or who have suffered events beyond the neonatal period, not related to prematurity, that could entail impairment in neurodevelopment (severe cranioencephalic trauma, oncological process, meningitis, or exposure to toxic substances)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748Daily dose of 6x109 UFC Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) from 7 days of life until reaching a postmenstrual age of 34 weeks or discharge
Primary Outcome Measures
NameTimeMethod
Degree of neurodevelopment at 6 years of age6 years

Behavior Rating Inventory of Executive Function, Second Edition (BRIEF2). Parent/teacher self reporting form.

Neuroplasticity biomarkers and intestinal permeability6 years

NeuN, Doublecortin, GFAP, GDNF, Ki67, Nrf2, BDNF, NGF, neurotrophin-1 (NT-1), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), DYRK1A, HIF1α, S100B i GSK3B. IL1B, IL6, IL8, IL10, IL12, TNF- α

Degree of neurodevelopment at 24 months corrected age24 months

Severe impairment will be attributed to subjects with any of the following: spastic quadriplegia, choreoathetosis, ataxia, Bayley score \<50, blindness or severe hypoacusis

Secondary Outcome Measures
NameTimeMethod
Incidence of necrotising enterocolitis40 weeks

cases fulfilling the stage II or above of the modified Bell's Criteria

Incidence of late onset sepsis40 weeks

positive blood culture beyond 72 hours of life

Incidence of Intraventricular haemorrhage40 weeks

Grade I-IV

Mortality40 weeks

Proportion of dead participants before discharge

Intensive care length of stay40 weeks

Days of intensive care

Trial Locations

Locations (1)

Neonataology Service, BCNatal Hospital Clinic Seu Maternitat

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath